- Conditions
- Healthy Volunteers
- Interventions
- TAK-881, HyQvia, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 10 more
- Conditions
- Pancreatic Adenocarcinoma Non-resectable
- Interventions
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Drug · Radiation
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- Up to 90 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-881, HYQVIA, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Cypress, California • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Daratumumab/rHuPH20
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 837
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus
- Interventions
- efgartigimod PH20 SC, Placebo, prednisone
- Biological · Other · Drug
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 16 more
- Conditions
- Neoplasms by Site
- Interventions
- nivolumab, rHuPH20
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Rockville, Maryland • Detroit, Michigan + 7 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Escondido, California • La Jolla, California • San Mateo, California + 16 more
- Conditions
- Dehydration
- Interventions
- recombinant human hyaluronidase
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 30 Days to 10 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 25
- States / cities
- Hartford, Connecticut • Orlando, Florida • Tampa, Florida + 20 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration
- Biological · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Pegylated Recombinant Human Hyaluronidase PH20, Pembrolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphedema, Malignant Neoplasm
- Interventions
- recombinant human hyaluronidase
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Melanoma
- Interventions
- Nivolumab/rHuPH20, Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Fort Wayne, Indiana • Knoxville, Tennessee
- Conditions
- AL Amyloidosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
- Procedure · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 117
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
- Conditions
- Dermatitis, Allergic Contact
- Interventions
- rHuPH20, Placebo
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Michigan City, Indiana
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Concord, California • Encino, California • Escondido, California + 18 more
- Conditions
- Risk Factors for or a Diagnosis of Osteoporosis
- Interventions
- rHuPH20, zoledronic acid
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
- Drug · Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
- Conditions
- Neoplasms
- Interventions
- Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 5
- States / cities
- West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more
- Conditions
- Pancreatic Ductal Carcinoma
- Interventions
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
- Other · Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
- Conditions
- Dehydration
- Interventions
- hylenex-facilitated subcutaneous Lactated Ringer's infusion
- Drug
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Lincoln, Nebraska • Neptune City, New Jersey
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- HYQVIA
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona